Mineralys Therapeutics Inc (NASDAQ: MLYS) started the day on Wednesday, with a price increase of 4.71% at $13.11, before settling in for the price of $12.52 at the close. Taking a more long-term approach, MLYS posted a 52-week range of $6.12-$16.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -83.84%. This publicly-traded company’s shares outstanding now amounts to $41.13 million, simultaneously with a float of $23.53 million. The organization now has a market capitalization sitting at $652.46 million. At the time of writing, stock’s 50-day Moving Average stood at $13.11, while the 200-day Moving Average is $12.83.
Mineralys Therapeutics Inc (MLYS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Mineralys Therapeutics Inc’s current insider ownership accounts for 52.72%, in contrast to 49.44% institutional ownership. According to the most recent insider trade that took place on Nov 11 ’24, this organization’s Chief Medical Officer sold 5,026 shares at the rate of 15.00, making the entire transaction reach 75,398 in total value, affecting insider ownership by 140,991.
Mineralys Therapeutics Inc (MLYS) Earnings and Revenue Records
Mineralys Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -83.84% and is forecasted to reach -3.91 in the upcoming year.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Let’s observe the current performance indicators for Mineralys Therapeutics Inc (MLYS). It’s Quick Ratio in the last reported quarter now stands at 8.55. The Stock has managed to achieve an average true range (ATR) of 0.83.
In the same vein, MLYS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.27, a figure that is expected to reach -1.06 in the next quarter, and analysts are predicting that it will be -3.91 at the market close of one year from today.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
If we take a close look at the recent performances of Mineralys Therapeutics Inc (NASDAQ: MLYS), its last 5-days Average volume was 0.16 million that shows plunge from its year to date volume of 0.18 million. During the previous 9 days, stock’s Stochastic %D was recorded 70.65% While, its Average True Range was 0.86.
Raw Stochastic average of Mineralys Therapeutics Inc (MLYS) in the period of the previous 100 days is set at 67.92%, which indicates a major rise in contrast to 48.40% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 92.95% that was higher than 70.72% volatility it exhibited in the past 100-days period.
